These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 9848508)

  • 21. Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor.
    Kennedy AR; Beazer-Barclay Y; Kinzler KW; Newberne PM
    Cancer Res; 1996 Feb; 56(4):679-82. PubMed ID: 8630994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies related to the potential antigenicity of the Bowman-Birk inhibitor, an anticarcinogenic protease inhibitor isolated from soybeans.
    Maki PA; Paterson Y; Kennedy AR
    Nutr Cancer; 1994; 22(2):185-93. PubMed ID: 14502847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of spermine-conjugated Bowman-Birk inhibitor (spermine-BBI) on carcinogenesis and cholesterol biosynthesis in mice.
    Kennedy AR; Kritchevsky D; Shen WC
    Pharm Res; 2003 Dec; 20(12):1908-10. PubMed ID: 14725352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor.
    St Clair WH; Billings PC; Carew JA; Keller-McGandy C; Newberne P; Kennedy AR
    Cancer Res; 1990 Feb; 50(3):580-6. PubMed ID: 2297699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis.
    Ware JH; Wan XS; Newberne P; Kennedy AR
    Dig Dis Sci; 1999 May; 44(5):986-90. PubMed ID: 10235608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth inhibition and cytotoxicity induced by Bowman-Birk inhibitor concentrate in cisplatin-resistant human ovarian cancer cells.
    Wan XS; Hamilton TC; Ware JH; Donahue JJ; Kennedy AR
    Nutr Cancer; 1998; 31(1):8-17. PubMed ID: 9682243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.
    Armstrong WB; Taylor TH; Kennedy AR; Melrose RJ; Messadi DV; Gu M; Le AD; Perloff M; Civantos F; Goodwin WJ; Wirth LJ; Kerr AR; Meyskens FL
    Cancer Prev Res (Phila); 2013 May; 6(5):410-8. PubMed ID: 23639862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.
    Armstrong WB; Wan XS; Kennedy AR; Taylor TH; Meyskens FL
    Laryngoscope; 2003 Oct; 113(10):1687-702. PubMed ID: 14520092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bowman-Birk inhibitors from legumes as colorectal chemopreventive agents.
    Clemente A; Arques Mdel C
    World J Gastroenterol; 2014 Aug; 20(30):10305-15. PubMed ID: 25132747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Internalisation of the Bowman-Birk protease inhibitor by intestinal epithelial cells.
    Billings PC; Brandon DL; Habres JM
    Eur J Cancer; 1991; 27(7):903-8. PubMed ID: 1834126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of tobacco smoke-induced lung tumors in mice fed Bowman-Birk protease inhibitor concentrate (BBIC).
    Witschi H; Espiritu I
    Cancer Lett; 2002 Sep; 183(2):141-6. PubMed ID: 12065088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine.
    Billings PC; Newberne PM; Kennedy AR
    Carcinogenesis; 1990 Jul; 11(7):1083-6. PubMed ID: 2372868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distribution of the Bowman Birk protease inhibitor in mice following oral administration.
    Billings PC; St Clair WH; Maki PA; Kennedy AR
    Cancer Lett; 1992 Mar; 62(3):191-7. PubMed ID: 1596863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complementary roles in cancer prevention: protease inhibitor makes the cancer preventive peptide lunasin bioavailable.
    Hsieh CC; Hernández-Ledesma B; Jeong HJ; Park JH; de Lumen BO
    PLoS One; 2010 Jan; 5(1):e8890. PubMed ID: 20126654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of oral carcinogenesis by a protease inhibitor.
    Messadi DV; Billings P; Shklar G; Kennedy AR
    J Natl Cancer Inst; 1986 Mar; 76(3):447-52. PubMed ID: 3081747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastric retention and stability of lipidized Bowman-Birk protease inhibitor in mice.
    Wang J; Shen WC
    Int J Pharm; 2000 Aug; 204(1-2):111-6. PubMed ID: 11011993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polylysine conjugates of Bowman-Birk protease inhibitor as targeted anti-carcinogenic agents.
    Persiani S; Yeung A; Shen WC; Kennedy AR
    Carcinogenesis; 1991 Jun; 12(6):1149-52. PubMed ID: 2044199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological significance of polymorphism in legume protease inhibitors from the Bowman-Birk family.
    Clementea A; Domoney C
    Curr Protein Pept Sci; 2006 Jun; 7(3):201-16. PubMed ID: 16787260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soybean Bowman-Birk protease inhibitor (BBI): identification of the mechanisms of BBI suppressive effect on growth of two adenocarcinoma cell lines: AGS and HT29.
    Fereidunian A; Sadeghalvad M; Oscoie MO; Mostafaie A
    Arch Med Res; 2014 Aug; 45(6):455-61. PubMed ID: 25014623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cationized Bowman-Birk protease inhibitor as a targeted cancer chemopreventive agent.
    Ekrami H; Kennedy AR; Witschi H; Shen WC
    J Drug Target; 1993; 1(1):41-9. PubMed ID: 8069543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.